← Eichor
Study identifier: NCT06241183 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Famotidine and Antacids for Treatment of Dyspepsia

Condition: Dyspepsia · GERD · Acid Reflux  ·  Sponsor: Stony Brook University

PhasePhase 4
Planned participants80
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox/ Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is for pain levels in both groups to decrease. It is expected that antacids will improve symptoms more quickly and to a greater degree within an hour of taking medication based on the results of similar studies.

This description comes directly from the study's public registry record.

Talk to the study team

Adam Singer, MD  ·  6314447857  ·  adam.singer@stonybrookmedicine.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Stony Brook University HospitalStony Brook, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06241183